Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656337 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EHRH3CHRM2 | |
| SCHEMBL2734116 | 0.98 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EHRH3CHRM2 | |
| SCHEMBL10159897 | 0.95 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KDM4EHRH3CHRM2 | |
| SCHEMBL12788388 | 0.94 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KDM4EHRH3CHRM2 | |
| SCHEMBL19958953 | 0.93 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2KDM4EHRH3CHRM2 | |
| SCHEMBL19958939 | 0.90 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2KDM4EHRH3CHRM2 | |
| SCHEMBL22560689 | 0.88 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2KDM4EHRH3CHRM2 | |
| SCHEMBL823898 | 0.86 | HRH3 (0.49) | ALDH1A1HRH3CYP2D6CYP2C19MEN1 | |
| SCHEMBL20234633 | 0.86 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2KDM4EHRH3CHRM2 | |
| SCHEMBL29314432 | 0.86 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2KDM4EHRH3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-07-10 | — | — | US | disclosed |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 2379/4885SMN1; SMN2 2486/4885KDM4E 4173/4885 |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | AHR, HCAR2, HCAR1 | ALDH1A1 273/4885SMN1; SMN2 3167/4885KDM4E 2403/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | ALDH1A1 1674/4885SMN1; SMN2 2512/4885KDM4E 4796/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | ALDH1A1 3735/4885SMN1; SMN2 4718/4885KDM4E 444/4885 |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | ALDH1A1 1472/4885SMN1; SMN2 4559/4885KDM4E 1022/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 4437/4885SMN1; SMN2 3728/4885KDM4E 3535/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | ALDH1A1 1472/4885SMN1; SMN2 4559/4885KDM4E 1022/4885 |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | ALDH1A1 1472/4885SMN1; SMN2 4559/4885KDM4E 1022/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ALDH1A1 128/4885SMN1; SMN2 1943/4885KDM4E 3895/4885 |
| US-20080153815-A1 | PINANE-SUBSTITUTED PYRIMIDINEDIAMINE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | ALDH1A1 4120/4885SMN1; SMN2 3487/4885KDM4E 4278/4885 |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | ALDH1A1 1472/4885SMN1; SMN2 4559/4885KDM4E 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.